Clinical observation of IMOP regimen in therapeutic effect on non-Hodgkin′s lymphoma

Objective: To evaluate the efficacy and toxicity of IMOP regimen to treat non-Hodgkin′s lymphoma. Methods: From march 1996 to march 1999, 81 cases with histologically and immunohistochemically proven non-Hodgkin′s lymphoma were analyzed retrospectively. They were divided into two groups: GroupⅠ, 41 cases were treated by IMOP regimen, it consisted of IFO 1.2 g/m2(i.v.drop.day1~5), MIT 10 mg/m2(i.v.day1), VCR1.4 mg/m2 (i.v.day1), Pred 40 mg/m2 (po.day1~5); Group Ⅱ, 40 cases were treated by CHOP regimen. it consisted of 750 mg/m2 (iv.drop.day1), ADM 40 mg/m2 (iv.day1), VCR 1.4 mg/m2 (iv.day1, 8), Pred 40 mg/m2(po.day1~5), Both groups were repeated every 3 weeks. Results: Patients in both group were well matched with baseline disease characteristics(P0.05). 81 cases with non-Hodgkin′s lymphoma entered into this study, 41 patients received IMOP regimen, the complete remission rate was 70%(29/41), the overall response rate was 87.8%(36/41)and the 5 year survived rate was 58.82%, 40 patients received CHOP regimen, the complete remission rate was 52.5%(21/40), the overall response rate was 65% (26/40) and the 5 year survive rate was 28.77%, There was a significant difference in the complete remission rate between the two groups (P0.05). The toxicity were myelosuppression, but there wasn′t a significant difference (P0.05). Conclusions: The results of this study demonstrate that IMOP regimen may be more effective than CHOP regimen. So this regimen can be considered as a effective regimen for non-Hodgkin′s lymphoma.